Board Member

David M. Rubenstein

David M. Rubenstein

Cofounder and Co-Chairman, The Carlyle Group

David M. Rubenstein is co-founder and co-chairman of the Carlyle Group, one of the world’s largest and most successful private investment firms. Established in 1987, Carlyle now manages $425 billion from twenty-eight offices around the world. Rubenstein is a Baltimore native and is the chairman and CEO of Major League Baseball’s Baltimore Orioles.

Rubenstein is chairman of the boards of the John F. Kennedy Center for the Performing Arts, the National Gallery of Art, the Economic Club of Washington, and the University of Chicago; a trustee of Memorial Sloan-Kettering Cancer Center, Johns Hopkins Medicine, the Institute for Advanced Study, the National Constitution Center, the Brookings Institution, and the World Economic Forum; and a director of the Lincoln Center for the Performing Arts and the American Academy of Arts and Sciences, among other board seats.

Rubenstein is a leader in Patriotic Philanthropy, having made transformative gifts for the restoration or repair of the Washington Monument, the Lincoln Memorial, the Jefferson Memorial, Monticello, Montpelier, Mount Vernon, Arlington House, the Iwo Jima Memorial, the Kennedy Center, the Smithsonian, the National Archives, the National Zoo, the Library of Congress, and the National Museum of African American History and Culture.

Rubenstein is an original signer of the Giving Pledge; the host of The David Rubenstein Show, Bloomberg Wealth with David Rubenstein, and Iconic America: Our Symbols and Stories with David Rubenstein; and the author of The American Story, How to Lead, The American Experiment, and How to Invest. 

Top Stories on CFR

Asia

Terrorism and Counterterrorism

Violence around U.S. elections in 2024 could not only destabilize American democracy but also embolden autocrats across the world. Jacob Ware recommends that political leaders take steps to shore up civic trust and remove the opportunity for violence ahead of the 2024 election season.

China

Those seeking to profit from fentanyl and governments seeking to control its supply are locked in a never-ending competition, with each new countermeasure spurring further innovation to circumvent it.